R21, developed by the University of Oxford and the Serum Institute of India, is now the second malaria vaccine to be recommended by the organisation following its approval of the RTS,S/AS01 vaccine in 2021.
Malaria, a mosquito-borne disease, places a particularly high burden on children in the African Region, where nearly half a million children die from the disease each year.
Despite “unprecedented” demand, WHO outlined that the available supply of RTS,S is limited and expects the addition of R21 to result in sufficient vaccine supply for children in areas where malaria is a public health risk…
